retatrutide powder where to buy Peptide For Research Retatrutide — Research Peptide (Lyophilised,

Obesity is known to increase the risk of cardiometabolic diseases and all-cause mortality significantly

Tirzepatide, a dual GIP/GLP-1 receptor agonist, has demonstrated greater efficacy in clinical trials, including the head-to-head SURMOUNT-5 trial comparing it to semaglutide 2.4 mg, potentially producing more substantial weight loss than traditional GLP-1 agonists alone

These immunobiotics have also been shown to reduce plasma T H 17 levels and inflammatory markers (Kanmani et al., 2024)

Unlike approved agents such as semaglutide (Wegovy) or tirzepatide (Zepbound), retatrutide has not yet received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for use in the United Kingdom